Please login to the form below

Not currently logged in
Email:
Password:

lurasidone

This page shows the latest lurasidone news and features for those working in and with pharma, biotech and healthcare.

EU approval for Takeda’s schizophrenia drug

EU approval for Takeda’s schizophrenia drug

Takeda and development partner Dainippon Sumitomo Pharma have won European approval for their schizophrenia treatment Latuda (lurasidone).

Latest news

  • GSK's diabetes drug among CHMP recommendations GSK's diabetes drug among CHMP recommendations

    2013. Takeda's antipsychotic and Linepharma's Hemoprostol. Elsewhere in the CHMP opinions, Takeda received a recommendation for the use of Latuda (lurasidone) in the treatment of adults with schizophrenia.

  • Schizophrenia treatments

    Lurasidone, an antagonist of dopamine D2, serotonin 2A, serotonin 7, serotonin 2C and a partial agonist of serotonin 1A, is being marketed by Sunovion Pharmaceuticals.

  • Coronary conundrums

    US. Lurasidone. Latuda (Sunovion Pharmaceuticals). Schizophrenia. US an Puerto Rico. Paracetamol.

  • DSP buys Sepracor

    The move comes as DSP prepares to launch its schizophrenia drug lurasidone, which last month significantly outperformed placebo in late-stage trials. ... The acquisition gives DSP the sales and marketing infrastructure in the US it needs to commercialise

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel (TAK-700),

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics